Skip to content

Federal Contractor Profile

Access To Advanced Health Institute

$40M obligated·21 awards·1 agencies·7 NAICS

Federal Contracts

Showing award actions 1–34 of 34 funded award actions, most recent first.

Contracts with positive obligations
21
Funded award actions shown
34
Obligations shown
$40M
Awarding agencies
1

This table shows award actions with a positive obligation. Zero-dollar and negative-dollar actions, such as administrative changes and deobligations, are not displayed. Multiple award actions may belong to the same contract.

Award data as of September 16, 2026. Source: USAspending federal award records.

DateAgencyPIIDNAICSDescriptionAmount
Sep 10, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$113K
Sep 10, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023C00018541715BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES$110K
Aug 16, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023C00018541715BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES$841K
Jul 22, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$1.9M
Jun 26, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023C00018541715BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES$2.8M
Mar 20, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$1.3M
Jan 9, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$780K
Aug 28, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$1.7M
Aug 28, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023C00018541715BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES$426K
Jul 5, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93023C00018541715BAA RESEARCH AREA 001: DEVELOPMENT OF VACCINE CANDIDATES FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES$810K
Aug 23, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$39K
Aug 1, 2022Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$3.5M
Nov 23, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$3.6M
Sep 14, 2021Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA75A50121C00087541714INFECTIOUS DISEASE RESEARCH INSTITUTE: R&D OF INTRANASAL ADMINISTRATION OF RNA VACCINES AGAINST RESPIRATORY PATHOGENS$749K
Sep 3, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93021P01305325414INVESTIGATIONAL PRODUCTS GLA-SE ADJUVANT FORMULATION AND LYOPHILIZED ID93 FROM IDRI FOR DAIDS-FUNDED CLINICAL TRIALS$781K
Jun 9, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$2.7M
Feb 18, 2021Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$2.9M
Sep 24, 2019Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00072541715BASE PERIOD, HARMONIZATION AND OPTIMIZATION OF STUDY PROTOCOLS AND ASSAY AND M72 BASE, MANUFACTURING ANDM72 OPTION 1A, MOUSE MODEL YEARS 1 AND 2.$5.7M
Aug 29, 2019Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019C00059541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$3.1M
Jul 26, 2019Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$753K
Jan 29, 2019Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019P00265325414IDRI VACCINE GRADE ADVUJANTPURCHASE 36 VIALS$11K
Jan 11, 2019Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93019F00131541714IN VITRO ASSESSMENTS OF ANTIMICROBIAL ACTIVITY.$3K
Sep 20, 2018Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMAHHSO100201000039C541711TAS::75 0140::TAS$343K
Sep 19, 2018Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018C00025541714IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.$2.7M
Aug 15, 2018Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAIDHHSN272201400041C541712IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS$2.3M
Jul 10, 2018Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018P00918325414LS130 AND EM082 LIPOSOMAL ADJUVANTS$5K
Jul 10, 2018Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018P00914325414LS130 LIPOSOMAL ADJUVANT, 25 UNITS$6K
May 4, 2018Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID75N93018P00664325414IDRI-LS130 LIPOSOMAL ADJUVANT, 42 VIALS$10K
Dec 7, 2017Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAIDHHSN272201400041C541712IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS$1.4M
Mar 22, 2017Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAIDHHSN272201400041C541712IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS$1.1M
Nov 4, 2016Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAIDHHSN27200005541711IGF::OT::IGF - 1100009I INFECTIOUS DISEASE RESEARCH INSTITUTE; IN VITRO ASSESSMENT FOR ANTIMICROBIAL ACTIVITY; TO A27 RDB--3; BIOD CAN 8470038; $638,080; PERIOD OF PERFORMANCE 11/04/2016 TO 10/31/2017$638K
Nov 3, 2016Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAIDHHSN272201400041C541712IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS$1.6M
Feb 18, 2016Department of Health and Human ServicesNIH, NIAID DEA OA OFC ACQUISITIONSHHSN272201600340P325413IGF::OT::IGF FOR OTHER FUNCTIONSINFECTIOUS DISEASE RESEARCH INSTITUTE$4K
Jan 28, 2016Department of Health and Human ServicesNIH, NIAID DEA OA OFC ACQUISITIONSHHSN272201400041C541712IGF::OT::IGF DEVELOPMENT OF VACCINE FORMULATIONS EFFECTIVE AGAINST NIAID PRIORITY PATHOGENS$1.7M

Get Alerted Before Access To Advanced Health Institute's Next Recompete

Mindy monitors active contracts and flags recompetes 12 months out so you can position to compete.

Start for free